A Versatile Discovery Platform
Sonnet BioTherapeutics is leveraging its proprietary platform to develop a pipeline of single- and bi-functional therapies capable of stimulating and/or blocking immune-modulating targets.
Sonnet Concept
Our technology leverages a scaffold based on our proprietary albumin-binding single chain antibody fragment (scFv) for delivery of recombinant human-cytokines (rH-cytokines) and other validated targets.
Following administration, the albumin-binding fragment attaches to naturally occurring albumin in the bloodstream and accumulates in inflamed tissue, including tumors.
By attaching a cytokine molecule to our albumin-binding fragment, we enable the cytokine to persist in the bloodstream and accumulate in the tumor micro-environment, affording it a greater chance to generate an anti-cancer immune response.
Customizable Platform to Drive Desired Immune Responses
Cytokine Payloads with Demonstrated Anti-Tumor Potential
IL-12 (Interleukin-12)
- Activates T cells and NK cells
- Reducing immunosuppression by conversion of M2→M1
- Enhancing anti-tumor effects by promoting Th1 differentiation and IFN-γ production, crucial for anti-tumor immunity
IL-18 (Interleukin-18)
- Activates T cells and NK cells
- Boosting local IFN-γ production and NK cell activity
- Works synergistically with IL-12 to enhance Th1 responses and overall anti-tumor immunity
- Increases chemokines CXCL9 & 10 expression which increases TH1, NK & CD8+ T cells infiltrate into tumors
IL-15 (Interleukin-15)
- Activates T cells and NK cells
- Enhances local T cell and NK cell activation without promoting Tregs
- Sustained and effective anti-tumor immunity by decreasing CD8 memory loss by apoptosis allowing long term immunosurveillance of the cancer
Enhanced Pharmacokinetic Characteristics
FHAB Has Shown to Extend Plasma Half-Life of Cytokine Payloads
AACR Annual Meeting 2017, Poster #588